Thomae

Dr. Karl Thomae GmbH, founded in 1893 and based in Biberach an der Riß, Germany, is a historic pharmaceutical company that became a cornerstone of Boehringer Ingelheim's global operations. The company gained international recognition for developing essential medicines such as the platelet inhibitor Persantin and the respiratory treatment Bisolvon. Following its acquisition and integration into Boehringer Ingelheim, the Biberach site has evolved into one of Europe's largest and most advanced centers for pharmaceutical research and biopharmaceutical production. Today, it serves as a primary hub for the development of innovative therapies, particularly in the fields of oncology, immunology, and cardiometabolic diseases. The facility is world-renowned for its large-scale cell culture capabilities and its role in manufacturing complex biologics for both internal programs and external partners.